NOT FOR HUMAN CONSUMPTION

LL-37 is the 37–amino-acid, C-terminal human cathelicidin peptide generated from the *CAMP* gene product hCAP18by proteolysis (e.g., proteinase-3). It is an amphipathic α-helical host-defense peptide (HDP) that combines direct, rapid microbicidal activity (bacteria, some fungi and enveloped viruses) with potent immunomodulation: chemotaxis, dendritic-cell licensing, angiogenesis, epithelial repair, endotoxin neutralization, and biofilm disruption. Unlike conventional antibiotics, LL-37 acts via membrane perturbation and immune signalling, reducing classical resistance pressure; however, organisms can adapt (surface charge remodeling, proteases). No LL-37 product is FDA/EMA-approved; several topical/inhaled candidates and analogs are in clinical development.

Additional Benefits of LL-37 Now Under Investigation

Benefit	Key take-aways
1 Broad-spectrum antimicrobial & antibiofilm	Rapid killing of Gram-positive/negative bacteria and biofilm disruption (including P. aeruginosa, S. aureus), with synergy to β-lactams, glycopeptides, and quinolones. <br/><em>Antimicrobial Agents & Chemotherapy; Journal of Antimicrobial Chemotherapy</em>
2 Endotoxin (LPS/LTA) neutralization	Direct binding to LPS/LTA blunts TLR4/2 signalling → lower TNF-α/IL-6; improves survival surrogates in endotoxemia models. <br/><em>Infection & Immunity; Shock</em>
3 Wound healing & re-epithelialization	Stimulates keratinocyte migration, angiogenesis (VEGF), and granulation tissue, accelerating closure of venous/diabetic ulcers in early clinical studies. <br/><em>Wound Repair & Regeneration; The Lancet EBioMedicine</em>
4 Antiviral activity (enveloped viruses)	Interferes with viral envelopes and enhances innate antiviral genes; in vitro activity vs influenza/RSV/coronaviruses; clinical translation ongoing. <br/><em>Journal of Virology; Frontiers in Immunology</em>
5 Respiratory host defense	Augments airway epithelial barrier, mucus clearance, and bacterial clearance; inhaled/neb formulations under study for CF/bronchiectasis colonization. <br/><em>American Journal of Respiratory Cell and Molecular Biology; Thorax</em>
6 Dental/periodontal applications	Reduces periodontal pathogens and biofilms; promotes gingival fibroblast repair, evaluated as a locally delivered adjunct to scaling/root planing. <br/><em>Journal of Clinical Periodontology; Journal of Periodontal Research</em>
7 Ophthalmology (infectious keratitis)	Topical LL-37 analogs enhance corneal epithelial healing and reduce microbial load in preclinical keratitis models. <br/><em>Investigative Ophthalmology & Visual Science; Cornea</em>
8 Anti-inflammatory immune tuning	Context-dependent modulation: boosts chemotaxis (via FPR2/ALX) and NET clearance, yet can limit excessive NF-κB activation, useful in chronic inflammatory wounds. <br/><em>Nature Communications; Journal of Immunology</em>
9 Oncology (bidirectional signals)	At micromolar ranges, LL-37 can be anti-tumoral (membranolysis, immune activation) in some cancers, yet pro-tumoral in others (e.g., pro-angiogenic in certain epithelial tumors); applications focus on tumor-selective analogs. <br/><em>Cancer Research; Oncogene</em>

2. Molecular Mechanism of Action

2.1 Pharmacodynamics / Receptors

Direct antimicrobial: Amphipathic helix inserts into microbial membranes → carpet/pore mechanisms → rapid lysis.
Pattern neutralization: Binds LPS/LTA and nucleic acids, reducing TLR over-activation.
Immunomodulation: Engages FPR2/ALX, P2X7, and transactivates EGFR on epithelia; chemoattracts neutrophils, monocytes, T cells; promotes angiogenesis.
Autoimmunity context: Complexes with self-DNA/RNA can trigger pDC TLR9/7 and type-I IFN, implicated in psoriasis pathogenesis (caution in susceptible patients).

2.2 Down-stream Biology

Pathway	Functional outcome	Context
Membrane perturbation	Bactericidal, antifungal, antiviral (enveloped)	Pathogens/biofilms
TLR decoy (LPS/LTA binding)	↓ NF-κB, ↓ TNF-α/IL-6	Sepsis/endotoxemia, wounds
FPR2/ALX signalling	Chemotaxis, angiogenesis, resolution cues	Neutrophils, endothelium
EGFR transactivation	Keratinocyte migration, re-epithelialization	Skin/cornea
P2X7 & NET modulation	NET clearance, controlled inflammasome	Innate immunity

3. Pharmacokinetics

Route/formulations: Topical gels/creams, wound dressings, intranasal/inhaled aerosols; parenteral use is experimental.
Half-life: Short minutes–hours in protease-rich environments (wounds, lung); activity extended by hydrogels, liposomes, PEGylation, D-amino-acid analogs, or cyclization.
Distribution: Predominantly local at administration site; strong binding to GAGs and extracellular matrix.
Clearance: Proteolysis (neutrophil elastase, trypsin-like proteases); minimal CYP involvement.

4. Pre-clinical and Translational Evidence

4.1 Chronic Wounds

Topical LL-37/analogs improved healing rates and time-to-closure in small RCTs of venous leg ulcers and pilot diabetic foot ulcer studies; reductions in bioburden and improved granulation were reported.

4.2 ENT / Respiratory

OP-145 (LL-37-derived) showed clinical signals in chronic suppurative otitis media; intranasal/inhaled candidates reduce pathogen burden and mucus viscosity in CF/bronchiectasis models.

4.3 Dentistry

Locally delivered LL-37 adjuncts improved clinical attachment level and reduced pathogen counts vs debridement alone in early trials.

4.4 Antiviral / ARI

In vitro inhibition of influenza and coronaviruses; small, phenotype-selected trials are exploring upper-airway symptom duration and viral load outcomes.

Evidence quality note: Many studies are early-phase/small; heterogeneity in peptide versions, delivery systems, and endpoints remains a limitation.

5. Emerging Clinical Interests

Field	Rationale	Current status
Chronic wounds (DFU/VLU)	Antibiofilm + pro-healing dual action	Phase 1/2; device-drug dressings
CF/bronchiectasis colonization	Inhaled antibiofilm therapy	Translational/early clinical
CRS/otitis media	Topical anti-infective with low resistance risk	Small clinical studies
Periodontitis/mucositis	Local antimicrobial + tissue repair	Pilot trials
Ophthalmic keratitis	Corneal healing + antimicrobial	Preclinical → early human feasibility
Sepsis adjunct	LPS neutralization and immune tuning	Preclinical/observational
Oncology (selective)	Tumor-targeted cytolysis/immune priming	Preclinical optimization

6. Safety and Tolerability

Common (topical): Mild stinging, erythema, transient pruritus.
Systemic/respiratory (investigational): Occasional cough/bronchial irritation with inhaled forms.
Cytotoxicity window: High micromolar levels can injure host cells, necessitates controlled delivery.
Autoimmune caution: LL-37–nucleic acid complexes may exacerbate psoriasis/lupus-like pathways in predisposed individuals.
Microbiome: More sparing than broad antiseptics; resistance risk exists (charge remodeling, proteases) but is lower/different than for antibiotics.

Comparative safety matrix

Concern	LL-37 (host-defense peptide)	Topical antibiotic (e.g., mupirocin)	Antiseptic (chlorhexidine/silver)
Biofilm penetration	High	Moderate	Low–moderate
Resistance selection	Low–moderate (non-classical)	Moderate–high	Low (but cytotoxic broadly)
Tissue repair effects	Pro-healing/angiogenic	Neutral	Often inhibitory/irritant
Microbiome disruption	Lower	Moderate	Higher (broad)
Irritation potential	Mild–moderate (dose-dependent)	Low	Variable; can be significant

7. Regulatory Landscape

Approvals: None (major markets).
Clinical programs: Topical gels/dressings and inhaled/nasal formulations in early trials; LL-37-derived analogs(e.g., OP-145, SAAP-class) advancing as antibiofilm agents.
Manufacturing: Peptide synthesis under GMP; stability and protease susceptibility drive formulation innovation.

8. Future Directions

Formulation engineering: Protease-resistant analogs, nanocarriers, and smart hydrogels for sustained local delivery.
Phenotype-guided trials: Target biofilm-heavy, chronic wounds, CF bronchiectasis, and recalcitrant sinus disease with standardized biofilm endpoints.
Combination therapy: Synergy with β-lactams/vancomycin/quinolones to shorten courses and curb resistance.
Biomarker strategy: Measure LPS-neutralization, cytokine signatures, and microbiome shifts alongside clinical outcomes.
Safety focus: Screen for autoimmune flare risk (psoriasis history), optimize local dosing windows.

Selected References

Antimicrobial Agents & Chemotherapy; Journal of Antimicrobial Chemotherapy, Antimicrobial and antibiofilm profiles, synergy with antibiotics.
Infection & Immunity; Shock, Endotoxin/LTA neutralization and cytokine modulation.
Wound Repair & Regeneration; The Lancet EBioMedicine, Clinical signals in venous/diabetic ulcers and tissue repair mechanisms.
American Journal of Respiratory Cell and Molecular Biology; Thorax, Airway defence and inhaled peptide studies.
Journal of Clinical Periodontology; Journal of Periodontal Research, Periodontal adjunctive therapy data.
Investigative Ophthalmology & Visual Science; Cornea, LL-37 analogs in corneal infection/repair.
Nature Communications; Journal of Immunology, FPR2/ALX signalling, immune tuning, NET biology.
Cancer Research; Oncogene, Context-dependent oncologic roles and tumor-selective analog development.

LL-37 5mg vial

Complete the setup